ArticleScientific reports2025
Identification of prognostic genes associated with phase separation in lung adenocarcinoma and construction of prognostic models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is a common histological subtype of lung cancer, but its prognosis remains poor. Recent studies have suggested that liquid-liquid phase separation-related genes (LRGs) can significantly predict the prognosis of low-grade tumors. Identifying potential LRGs associated with prognosis in LUAD could have significant clinical value for predicting patient outcomes. Data were sourced from public databases. Differentially expressed LRGs (DE-LRGs) were identified through differential expression analysis and by taking intersections between datasets. Regression analysis and the Least Absolute Shrinkage and Selection Operator (Lasso) method were used to shortlist prognostic genes, and a multivariate Cox regression model was developed to create a prognostic risk model. Tumor samples were stratified into high- and low-risk groups based on the median risk score. Independent prognostic analyses and the construction of a nomogram were performed in conjunction with clinical characteristics. Immune characteristics of the two risk groups were also analyzed. Additionally, single-cell RNA sequencing (scRNA-seq) data were used to identify cell clusters and annotate known cell types. A total of 389 DE-LRGs were identified, and 7 prognostic genes were selected to construct the risk model. Patients in the high-risk group exhibited lower survival rates, and the nomogram demonstrated high predictive accuracy. Significant differences were observed in clinical characteristics, immune status, and drug sensitivity between the high- and low-risk groups. Based on scRNA-seq data, 8 distinct cell types were annotated, with the prognostic genes GRIA1 and BCAN showing higher expression levels in fibroblasts and mast cells, respectively. Seven prognostic genes were identified, and the resulting prognostic model accurately predicted the survival outcomes of LUAD patients. This model provides valuable insights for the prognosis and personalized treatment of LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.